St. Louis Arch Angels
VC Fund
St Louis, United States
St. Louis Arch Angels is a VC fund in St Louis focused on Biotechnology and Health Care. We are a select group of accredited investors with diverse expertise and experience, seeking high potential start-up ventures drawn from the St. Louis startup ecosystem to fund and support, resulting in success of our funded companies and outsized returns for our members and corporate partners.
- Total investments:
- 76
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries St. Louis Arch Angels invests in
Stages St. Louis Arch Angels invests in
Countries St. Louis Arch Angels invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $100k–$3.3M
- Series A
- $1.5M–$8.5M
Investment Focus
Industry
- Biotechnology 26 (34%)
- Health Care 25 (33%)
- Medical Device 12 (16%)
- Software 11 (14%)
- Medical 10 (13%)
Stage
- Seed 44 (58%)
- Series A 9 (12%)
- Funding Round 6 (8%)
- Angel 4 (5%)
- Series B 4 (5%)
Country
- United States 64 (84%)
- Argentina 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Kinman
Chairman and CEO
|
Chairman and CEO | Total investments: 3 | Find email | |
Gilbert Bickel
Chairman
|
Chairman | Total investments: 0 | Find email | |
Robert Calcaterra
President
|
President | Total investments: 0 | Find email | |
|
Thomas M. Walsh
Secretary
|
Secretary | Total investments: 0 | Find email | |
William Rusnack
Treasurer
|
Treasurer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Maximum Fidelity Surgical Simulations
|
Maximum Fidelity Surgical Simulations manufactures medical, surgical, ophthalmic, and veterinary instruments and apparatus. It prepares medical personnel for military trauma, test biomedical devices, and provides hyper-realistic medical education using a lifelike patient and without endangering human life. | $2.3M / Seed / Jul 09, 2024 | |
|
Maximum Fidelity Surgical Simulations
|
Maximum Fidelity Surgical Simulations manufactures medical, surgical, ophthalmic, and veterinary instruments and apparatus. It prepares medical personnel for military trauma, test biomedical devices, and provides hyper-realistic medical education using a lifelike patient and without endangering human life. | $2.3M / Seed / Jul 09, 2024 | |
Peptyde Bio
|
Peptyde Bio is an Agtech startup positioned to become the go-to supplier of new AMPs. | $1.2M / Pre-Seed / Nov 15, 2022 | |
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $500K / Venture - Series Unknown / Jul 27, 2021 | |
Impetus Agriculture
|
Impetus Agriculture focuses on developing multiple topical or transgenic insect control products. Products that are safe, effective, and sustainable. Products that are not subject to the same insect resistance that has developed in current commercial products. | $1M / Seed / Jun 04, 2021 | |
Sequoia Sciences
|
Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers. Their development programs consist of small molecules targeting bacterial infections and cancers, and also vaccines for the treatment and prevention of recurrent urinary tract infections. Their goal is toimprove the quality of life for those individuals significantly affected by recurrent and chronic bacterial infections and cancers.Sequoia is engaged in research and development programs and collaborations with laboratories, universities, clinical research sites, and private businesses. They have applied their microscale structure determination expertise to elucidate structures of natural products, biosynthetic intermediates, and unexpected synthetic products for academic and industrial collaborators. | $72K / Seed / Jul 27, 2020 | |
Amplified Sciences
|
Amplified Sciences is a molecular diagnostics company unlike other diagnostics companies due to their ultra-sensitive molecular sensing technology with composition of matter IP exclusively licensed from Purdue University. The technology is disease state agnostic, can detect to the single molecule level, scales easily to point of care, and providesa very favorable cost structure for their platform of reagents. The first application – early detection of pancreatic cancer - is an assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path. The team has delivered a working prototype and published proof of concept data. | $1M / Seed / Apr 24, 2020 | |
Covercress
|
CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture.CoverCress was founded in 2013 byJerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri. | $5M / Venture - Series Unknown / Apr 13, 2020 | |
FinLocker
|
FinLocker is a financial services technology innovator, founded by a team of veterans and executives across the financial services and technology industries. It provides a personal financial assistant tool that enables loans and financial transactions. With consumer consent, FinLocker captures key borrower data and applies intelligent analyticssuch as loan product recommendations based on a consumer’s financial profile, asset and income verification, and more. The company was founded in 2014 and is headquartered in St Louis, Missouri. | $10.4M / Seed / Nov 20, 2019 | |
|
FinLocker
|
FinLocker is a financial services technology innovator, founded by a team of veterans and executives across the financial services and technology industries. It provides a personal financial assistant tool that enables loans and financial transactions. With consumer consent, FinLocker captures key borrower data and applies intelligent analyticssuch as loan product recommendations based on a consumer’s financial profile, asset and income verification, and more. The company was founded in 2014 and is headquartered in St Louis, Missouri. | $10.4M / Nov 20, 2019 | |
| See all 76 investments → | |||
Co-Investors
Missouri Technology Corporation
16 deals together
BioGenerator
12 deals together
Cultivation Capital
11 deals together
The Yield Lab
6 deals together
Billiken Angels Network
5 deals together
iSelect Fund
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does St. Louis Arch Angels invest in?
St. Louis Arch Angels invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 76 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is St. Louis Arch Angels's check size?
St. Louis Arch Angels typically joins rounds of $100k–$3.3M at Seed and $1.5M–$8.5M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds St. Louis Arch Angels participates in.
How do I contact St. Louis Arch Angels?
Public channels for St. Louis Arch Angels include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at St. Louis Arch Angels?
The team at St. Louis Arch Angels includes Brian Kinman (Chairman and CEO), Gilbert Bickel (Chairman) and Robert Calcaterra (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
